Skip to main content

Using Exploratory Visualization in the Analysis of Medical Product Safety in Observational Healthcare Data

  • 1948 Accesses

Abstract

Increasing the knowledge about the safety of medical products remains a top priority throughout the pharmaceutical development life cycle and particularly after regulatory approval when the products are used in real-world populations. The increasing availability and use of observational healthcare data, such as administrative claims and electronic health records, provides opportunity for generating ­better information to support therapeutic decision-making. Analysis of observational databases is quite different from randomized clinical trials, and offers unique opportunities for exploratory visualization to complement traditional epidemiologic investigations. The Observational Medical Outcomes Partnership was established to conduct methodological research on the appropriate use of observational data to identify and evaluate the effects of medical products in the real world. Several visualization tools were developed throughout the process, which demonstrate the value in combining standardized analytics with interactive graphics. These tools include a patient profile to study longitudinal patterns within clinical observations for a given person; a cohort profile to evaluate collections of patients; a treemap to assess ­disease prevalence across a database; a trellis scatterplot to investigate subgroup differences in drug utilization; a heatmap to support evaluation of high-dimensional confounding adjustment; and a multi-method forest plot to enable sensitivity analyses of estimated effects of drug and outcomes. This chapter illustrates these visualizations through a case study exploring the relationship between ACE inhibitor exposure and the subsequent health event angioedema.

Keywords

  • Angiotensin Convert Enzyme
  • Angiotensin Convert Enzyme Inhibitor
  • Electronic Health Record
  • Patient Profile
  • Electronic Health Record System

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-4614-5329-1_21
  • Chapter length: 23 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   149.00
Price excludes VAT (USA)
  • ISBN: 978-1-4614-5329-1
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   199.99
Price excludes VAT (USA)
Hardcover Book
USD   249.99
Price excludes VAT (USA)
Fig. 21.1
Fig. 21.2
Fig. 21.3
Fig. 21.4
Fig. 21.5
Fig. 21.6
Fig. 21.7
Fig. 21.8
Fig. 21.9

References

  • Agbabiaka TB, Savovic J, Ernst E (2008) Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 31(1):21–37

    PubMed  CrossRef  Google Scholar 

  • ALLHAT (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23):2981–2997

    CrossRef  Google Scholar 

  • Almenoff J, Tonning JM, Gould AL et al (2005) Perspectives on the use of data mining in pharmacovigilance. Drug Saf 28(11):981–1007

    PubMed  CrossRef  CAS  Google Scholar 

  • Arimone Y, Miremont-Salame G, Haramburu F et al (2007) Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br J Clin Pharmacol 64(4):482–488

    PubMed  CrossRef  Google Scholar 

  • Bandekar MS, Anwikar SR, Kshirsagar NA (2010) Quality check of spontaneous adverse drug reaction reporting forms of different countries. Pharmacoepidemiol Drug Saf 19(11):1181–1185

    PubMed  CrossRef  CAS  Google Scholar 

  • Bennett CL, Nebeker JR, Yarnold PR et al (2007) Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med 167(10):1041–1049

    PubMed  CrossRef  Google Scholar 

  • Berlin JA, Glasser SC, Ellenberg SS (2008) Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health 98(8):1366–1371

    PubMed  CrossRef  Google Scholar 

  • Brown NJ, Ray WA, Snowden M, Griffin MR (1996) Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 60(1):8–13

    PubMed  CrossRef  CAS  Google Scholar 

  • Chalmers D, Whitehead A, Lawson DH (1992) Postmarketing surveillance of captopril for hypertension. Br J Clin Pharmacol 34(3):215–223

    PubMed  CrossRef  CAS  Google Scholar 

  • Chobanian A (2009) The joint national committee on prevention detection and evaluation of high blood pressure. US Department of Health and Human Services NHLBI, Bethesda, MD

    Google Scholar 

  • Chou R, Helfand M, Carson S (1995) Drug class review on angiotensin converting enzyme inhibitors. Final report. Portland, OR: Oregon Health & Science University

    Google Scholar 

  • DuMouchel W (1999) Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Statist 53(3):177–189

    Google Scholar 

  • Foody JM, Mendys PM, Liu LZ, Simpson RJ Jr (2010) The utility of observational studies in clinical decision making: lessons learned from statin trials. Postgrad Med 122(3):222–229

    PubMed  CrossRef  Google Scholar 

  • Hennessy S (2006) Use of health care databases in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 98(3):311–313

    PubMed  CrossRef  CAS  Google Scholar 

  • Hennessy S, Leonard CE, Palumbo CM, Newcomb C, Bilker WB (2007) Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care 45(12):1216–1220

    PubMed  CrossRef  Google Scholar 

  • Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–300

    PubMed  CAS  Google Scholar 

  • Knapp P, Raynor DK, Berry DC (2004) Comparison of two methods of presenting risk information to patients about the side effects of medicines. Qual Saf Health Care 13(3):176–180

    PubMed  CrossRef  CAS  Google Scholar 

  • Kostis JB, Shelton B, Gosselin G et al (1996) Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 131(2):350–355

    PubMed  CrossRef  CAS  Google Scholar 

  • Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15):1200–1205

    PubMed  CrossRef  CAS  Google Scholar 

  • Lewis JD, Brensinger C (2004) Agreement between GPRD smoking data: a survey of general practitioners and a population-based survey. Pharmacoepidemiol Drug Saf 13(7):437–441

    PubMed  CrossRef  Google Scholar 

  • Madigan D, Ryan P (2011) What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research. Epidemiology 22(5):629–631

    PubMed  CrossRef  Google Scholar 

  • Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE (2008) Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 51(6):1624–1630

    PubMed  CrossRef  CAS  Google Scholar 

  • Norén G, Bate A, Hopstadius J, Star K, Edwards I (2008) Temporal pattern discovery for trends and transient effects: its application to patient records. Paper presented at: Proceeding of the 14th ACM SIGKDD international conference on knowledge discovery and data mining, Las Vegas, Nevada, USA

    Google Scholar 

  • Norris S, Weinstein J, Peterson K, Thakurta S (2010) Drug class review: direct renin inhibitors, angiotensin converting enzyme inhibitors, and angiotensin II receptor blockers. Accessed on Oct 8, 2012, http://derp.ohsu.edu/about/fi nal-document-display.cfm Accessed Oct 8, 2012.

  • Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE (2011) Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 19(1):54–60

    PubMed  CrossRef  Google Scholar 

  • Public Law 110–85 (2007) Food and Drug Administration Amendments Act of 2007

    Google Scholar 

  • Papay JI, Clines D, Rafi R et al (2009) Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol 54(1):84–90

    PubMed  CrossRef  CAS  Google Scholar 

  • Perrio M, Voss S, Shakir SA (2007) Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance. Drug Saf 30(4):333–346

    PubMed  CrossRef  CAS  Google Scholar 

  • Polinski JM, Schneeweiss S, Levin R, Shrank WH (2009) Completeness of retail pharmacy claims data: implications for pharmacoepidemiologic studies and pharmacy practice in elderly patients. Clin Ther 31(9):2048–2059

    PubMed  CrossRef  Google Scholar 

  • Racoosin J (2009) FDA’s sentinel initiative—a national strategy for monitoring medical product safety. 2nd Drug Information Association (DIA) Conference on Signal Detection and Data Mining. New York, NY

    Google Scholar 

  • Rockhill B, Newman B, Weinberg C (1998) Use and misuse of population attributable fractions. Am J Public Health 88(1):15–19

    PubMed  CrossRef  CAS  Google Scholar 

  • Rodriguez EM, Staffa JA, Graham DJ (2001) The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf 10(5):407–410

    PubMed  CrossRef  CAS  Google Scholar 

  • Rosenbaum P (2002) Observational studies. Springer, New York

    Google Scholar 

  • Schneeweiss S (2009) On guidelines for comparative effectiveness research using nonrandomized studies in secondary data sources. Value Health 10 Sep 2009

    Google Scholar 

  • Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA (2009) High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20(4):512–522

    PubMed  CrossRef  Google Scholar 

  • Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323–337

    PubMed  CrossRef  Google Scholar 

  • Schneeweiss S, Sturmer T, Maclure M (1997) Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 6(Suppl 3):S51–S59

    PubMed  CrossRef  Google Scholar 

  • Speirs C, Wagniart F, Poggi L (1998) Perindopril postmarketing surveillance: a 12 month study in 47,351 hypertensive patients. Br J Clin Pharmacol 46(1):63–70

    PubMed  CrossRef  CAS  Google Scholar 

  • Stang PE, Ryan PB, Racoosin JA et al (2010) Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 153(9):600–606

    PubMed  Google Scholar 

  • Strom B (2005) Pharmacoepidemiology, 4th edn. Wiley, Chichester

    Google Scholar 

  • Suissa S, Garbe E (2007) Primer: administrative health databases in observational studies of drug effects—advantages and disadvantages. Nat Clin Pract Rheumatol 3(12):725–732

    PubMed  CrossRef  CAS  Google Scholar 

  • Szarfman A, Machado SG, O’Neill RT (2002) Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf 25(6):381–392

    PubMed  CrossRef  CAS  Google Scholar 

  • US Department of Health and Human Services, Food and Drug Administration (1999) Managing the risks from medical product use: creating a risk management framework US Department of Health and Human Services, Food and Drug Administration, May 1999

    Google Scholar 

  • Waller PC, Evans SJ (2003) A model for the future conduct of pharmacovigilance. Pharmacoepi­demiol Drug Saf 12(1):17–29

    PubMed  CrossRef  Google Scholar 

  • Weatherby LB, Nordstrom BL, Fife D, Walker AM (2002) The impact of wording in “Dear doctor” letters and in black box labels. Clin Pharmacol Ther 72(6):735–742

    PubMed  CrossRef  Google Scholar 

  • Whitaker HJ, Farrington CP, Spiessens B, Musonda P (2006) Tutorial in biostatistics: the self-controlled case series method. Stat Med 25(10):1768–1797

    PubMed  CrossRef  Google Scholar 

  • Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342(3):145–153

    PubMed  CrossRef  CAS  Google Scholar 

  • Zorych I, Madigan D, Ryan P, Bate A (2011) Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res (in print)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Patrick Ryan .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2012 Springer Science+Business Media, New York

About this chapter

Cite this chapter

Ryan, P. (2012). Using Exploratory Visualization in the Analysis of Medical Product Safety in Observational Healthcare Data. In: Krause, A., O'Connell, M. (eds) A Picture is Worth a Thousand Tables. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-5329-1_21

Download citation